0RIS Circio Holding Asa

OSLO, Norway, Oct. 1, 2018 /PRNewswire/ --

Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company presented at the following conference:

13th International Adenovirus Meeting
Date: 27 September 2018
Presenter: Lukasz Kuryk, Director Clinical Science
Poster session: 20:00 – 23:00  
Venue: San José Vista Hermosa, Mexico

Abstract title: "Anti-tumor specific T-cell responses induced by oncolytic adenovirus ONCOS-102 in peritoneal mesothelioma mouse model"
Please see the poster below:

1809 Poster ONCOS-102

Contact:

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com  

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/targovax/r/targovax-presented-oncos-102-poster-at-13th-international-adenovirus-meeting,c2632463

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/targovax-presented-oncos-102-poster-at-13th-international-adenovirus-meeting-300721691.html

SOURCE Targovax